PF-04523655 targets Quark's proprietary gene, RTP801, discovered using its BiFAR TM target discovery platform that identifies clinically relevant critical genes and proteins that reverse the disease phenotype when inhibited. The siRNA therapeutic candidate was licensed to Pfizer in 2006 and both trials are being conducted by Pfizer in collaboration with Quark. Quark's pipeline is led by PF-04523655, currently in two Phase II clinical trials for the treatment of wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Quark's approach to delivery allows targeting of tissues and organs including the eye, kidney, ear, lung, spinal cord and brain. The Company's fully integrated drug development platform spans therapeutic target identification to drug development. Quark Pharmaceuticals, Inc., the world leader in novel RNAi discovery and development, has the largest clinical-stage siRNA pipeline in the industry. On behalf of our board of directors, I would also like to welcome Mr.
Daniel Zurr, Quark's Chief Executive Officer, stated, "We are pleased to close our latest financing round and remain well-capitalized to advance our promising siRNA drug candidates through the clinic. The Company's pipeline candidates are currently being evaluated in five different clinical trials.ĭr. Quark Pharmaceuticals will use the funds to advance its RNAi drug pipeline, which has the largest number of clinical-stage siRNA therapeutic programs in the industry. Since our previous investment in 2008, when Quark had a promising preclinical-stage RNAi drug pipeline, the Company has brought five clinical programs into the clinic and has more siRNA drug candidates in the clinic than any other RNAi company." Yoshitaka Kitao, CEO of SBI Holdings, Inc., commented, "We are impressed with Quark's significant progress since our initial investment, and we look forward to further supporting the Company and its rapidly growing clinical programs.
will become members of the Quark board of directors. Robert Takeuchi, Director of SBI Investment Co., Ltd. Yoshitaka Kitao, CEO of SBI Holdings, Inc. The investors are funds of the prestigious SBI Holdings Group in Japan. CEO Yoshitaka Kitao Appointed to Boardįunds to Support Advancing Clinical PipelineįREMONT, Calif., June 10 /PRNewswire/ - Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced the closing of a private financing by the existing investors of Quark totaling an aggregate of $10 million. Quark Pharmaceuticals Closes $10 Million Financing
0 kommentar(er)
